Treatment schedule during the double-blind phase (beginning at baseline, day 1)
Pbo, Placebo; PP, paliperidone palmitate; RIS-LAI, risperidone long-acting injectable.
The doses expressed as 25, 50, and 75 mg eq. PP equate to 39, 78, and 117 mg PP, respectively.
All injections were administered intramuscularly at the gluteal site.
Patients in PP group continued to receive either flexibly dosed PP or placebo injection every 2 wk from week 11 up to week 51.
Patients in the RIS-LAI group continued to receive RIS-LAI injections every 2 wk from week 11 up to week 51.
Oral supplementation (risperidone 1–6 mg/placebo) was given for the first 4 wk of the double-blind treatment period. Oral supplementation (risperidone 1–4 mg/placebo) was also given at any dose increase from day 36 onwards, continuing for up to 3 wk.
Treatment schedule during the double-blind phase (beginning at baseline, day 1)
Pbo, Placebo; PP, paliperidone palmitate; RIS-LAI, risperidone long-acting injectable.
The doses expressed as 25, 50, and 75 mg eq. PP equate to 39, 78, and 117 mg PP, respectively.
All injections were administered intramuscularly at the gluteal site.
Patients in PP group continued to receive either flexibly dosed PP or placebo injection every 2 wk from week 11 up to week 51.
Patients in the RIS-LAI group continued to receive RIS-LAI injections every 2 wk from week 11 up to week 51.
Oral supplementation (risperidone 1–6 mg/placebo) was given for the first 4 wk of the double-blind treatment period. Oral supplementation (risperidone 1–4 mg/placebo) was also given at any dose increase from day 36 onwards, continuing for up to 3 wk.
